LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended authorising Imfinzi in combination with Imjudo for 1st-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma; and Imfinzi in combination with Imjudo and platinum-based chemotherapy for the treatment of adult patients with Stage IV non-small cell lung cancer. The positive opinions were based on significant survival benefit in HIMALAYA and POSEIDON Phase III trials.
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: 'If approved, these Imjudo and Imfinzi combinations will provide patients with novel options that harness the potential long-term survival benefits seen with CTLA-4 inhibition.'
For More Such Health News, visit rttnews.com.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2022 AFX News